This activity is provided by Med Learning Group.
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Copyright © 2024 Med Learning Group. Built by Divigner. All Rights Reserved.
Key Updates in Bispecific Antibodies in NHL Management—Unmet Needs and Opportunities for Improved Management in Later-Line Management
TeleECHO Smart Reach Replay Enduring
Podcast 1: Clinical application of novel bispecific antibody therapies to the management of NHL
Podcast 2: Update on latest available clinical trial data surrounding the management of NHL using novel bispecific antibody therapies
TeleECHO Smart Reach Replay Enduring
FACULTY
Mazyar Shadman, MD, MPH
Associate Professor, Division of Medical Oncology
University of Washington School of Medicine
Associate Professor, Clinical Research Division
Fred Hutch Cancer Center
Seattle, WA
PROGRAM OVERVIEW
This enduring TeleECHO educational series is designed to assist members of the multi-disciplinary oncology care team in identifying approaches to the use of novel bispecific antibody therapies in later-line management of B-cell non-Hodgkin’s lymphoma (NHL). This program features expert analysis of the latest clinical trial outcomes and potential adverse events associated with bispecific antibody therapy, as well as discussion of best practices for multidisciplinary management of B-cell NHL to improve long-term clinical outcomes.
TARGET AUDIENCE
This activity is designed to meet the educational needs of community-based medical oncologists, hematologists, nurse practitioners, pharmacists, and other members of the multi-disciplinary oncology care team.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Recognize approaches to use of novel bispecific antibody therapies in the management of NHL
- Analyze the latest outcomes of clinical trials in NHL incorporating bispecific antibody therapy
- Summarize the latest data concerning potential adverse events associated with novel bispecific antibodies in NHL
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
CONTINUING EDUCATION LANGUAGE
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NURSES (ANCC) Credit Designation
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
Mazyar Shadman, MD discloses that he is a consultant for AbbVie, Genentech, AstraZeneca, Pharmacyclis, BeiGene, Bristol Myers Squibb, MorphoSys/Incyte, Kite, Eli Lilly, Genmab, Mustang Bio, Regeneron and ADC Therapeutics. Dr. Shadman has conducted contracted research for Mustang Bio, Bristol Myers Squibb, Pharmacyclics, Genentech, AbbVie, TG Therapeutics, BeiGene, AstraZeneca, Genmab, MorphoSys/Incyte and Vincerx.
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
- Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
- Nicole Longo, DO, FACOI, VP of Med/Sci Services and Learner Engagement of Med Learning Group, has nothing to disclose.
- Sunali Wadehra, MD, Medical Director of Med Learning Group, has nothing to disclose.
- Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
- Jessica Feygin, Program Coordinator of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
- Daniel DaSilva, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: January 26, 2024
EXPIRATION DATE: January 26, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
Podcast 1: Clinical application of novel bispecific antibody therapies to the management of NHL
PROGRAM CHAIRS
Farrukh T. Awan, MD
Professor of Internal Medicine
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, TX
Mazyar Shadman, MD, MPH
Associate Professor, Division of Medical Oncology
University of Washington School of Medicine
Associate Professor, Clinical Research Division
Fred Hutch Cancer Center
Seattle, WA
PROGRAM OVERVIEW
These podcasts are designed to assist members of the multi-disciplinary oncology care team in identifying approaches to the use of novel bispecific antibody therapies in later-line management of B-cell non-Hodgkin’s lymphoma (NHL). This program features expert analysis of the latest clinical trial outcomes and potential adverse events associated with bispecific antibody therapy, as well as guidance on treatment approaches that incorporate the use of bispecific antibody therapy into treatment planning.
TARGET AUDIENCE
This activity is designed to meet the educational needs of community-based medical oncologists, hematologists, nurse practitioners, pharmacists, and other members of the multi-disciplinary oncology care team.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Recognize approaches to use of novel bispecific antibody therapies in the management of NHL
- Summarize the latest data concerning potential adverse events associated with novel bispecific antibodies in NHL
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.25 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
| Faculty Member | Disclosures |
| Farrukh Awan, MD | Discloses that he has received consulting fees from Genentech, AstraZeneca, AbbVie, Janssen, Pharmacyclics, Gilead Sciences, Kite Pharma, Celgene, Karyopharm, MEI Pharma, Verastem Oncology, Incyte, BeiGene, Johnson & Johnson, DAVA Oncology, Bristol Myers Squibb, Merck, Cardinal Health, ADCT therapeutics, Epizyme, Caribou Biosciences, Cellectar Bisosciences, Loxo Oncology, Adaptive Biotechnologies, and Genmab. Dr. Awan has conducted research for Pharmacyclics. |
| Mazyar Shadman, MD | Discloses that he is a consultant for AbbVie, Genentech, AstraZeneca, Pharmacyclics, BeiGene, Bristol Myers Squibb, MorphoSys/Incyte, Kite Pharma, Eli Lilly, Genmab, MustangBio, Regeneron, and ADC Therapeutics. Dr. Shadman has conducted contracted research for MustangBio, Bristol Myers Squibb, Pharmacyclics, Genentech, AbbVie, TG Therapeutics, BeiGene, AstraZeneca, Genmab, MorphoSys/Incyte, and Vincerx Pharma. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Shannon Mutch MS, RN, OCN, has nothing to disclose.
- Mike Milano, MD has received royalties from Wolters Kluwer (UpToDate author royalties)
A medical reviewer from CME Peer Review LLC, has nothing to disclose. - Nicole Longo, DO, FACOI, VP of Med/Sci Services and Learner Engagement of Med Learning Group, has nothing to disclose.
- Sunali Wahedra, MD, Medical Director of Med Learning Group, has nothing to disclose.
- Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
- Jessica Feygin, Associate Program Manager of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
- Daniel DaSilva, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
Please listen to the podcast below:
RELEASED DATE: January 26, 2024
EXPIRATION DATE: January 26, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
Podcast 2: Update on latest available clinical trial data surrounding the management of NHL using novel bispecific antibody therapies
PROGRAM CHAIRS
Farrukh T. Awan, MD
Professor of Internal Medicine
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, TX
Mazyar Shadman, MD, MPH
Associate Professor, Division of Medical Oncology
University of Washington School of Medicine
Associate Professor, Clinical Research Division
Fred Hutch Cancer Center
Seattle, WA
PROGRAM OVERVIEW
These podcasts are designed to assist members of the multi-disciplinary oncology care team in identifying approaches to the use of novel bispecific antibody therapies in later-line management of B-cell non-Hodgkin’s lymphoma (NHL). This program features expert analysis of the latest clinical trial outcomes and potential adverse events associated with bispecific antibody therapy, as well as guidance on treatment approaches that incorporate the use of bispecific antibody therapy into treatment planning.
TARGET AUDIENCE
This activity is designed to meet the educational needs of community-based medical oncologists, hematologists, nurse practitioners, pharmacists, and other members of the multi-disciplinary oncology care team.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Analyze the latest outcomes of clinical trials in NHL incorporating bispecific antibody therapy
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.25 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
| Faculty Member | Disclosures |
| Farrukh Awan, MD | Discloses that he has received consulting fees from Genentech, AstraZeneca, AbbVie, Janssen, Pharmacyclics, Gilead Sciences, Kite Pharma, Celgene, Karyopharm, MEI Pharma, Verastem Oncology, Incyte, BeiGene, Johnson & Johnson, DAVA Oncology, Bristol Myers Squibb, Merck, Cardinal Health, ADCT therapeutics, Epizyme, Caribou Biosciences, Cellectar Bisosciences, Loxo Oncology, Adaptive Biotechnologies, and Genmab. Dr. Awan has conducted research for Pharmacyclics. |
| Mazyar Shadman, MD | Discloses that he is a consultant for AbbVie, Genentech, AstraZeneca, Pharmacyclics, BeiGene, Bristol Myers Squibb, MorphoSys/Incyte, Kite Pharma, Eli Lilly, Genmab, MustangBio, Regeneron, and ADC Therapeutics. Dr. Shadman has conducted contracted research for MustangBio, Bristol Myers Squibb, Pharmacyclics, Genentech, AbbVie, TG Therapeutics, BeiGene, AstraZeneca, Genmab, MorphoSys/Incyte, and Vincerx Pharma. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Shannon Mutch MS, RN, OCN, has nothing to disclose.
- Mike Milano, MD has received royalties from Wolters Kluwer (UpToDate author royalties)
A medical reviewer from CME Peer Review LLC, has nothing to disclose. - Nicole Longo, DO, FACOI, VP of Med/Sci Services and Learner Engagement of Med Learning Group, has nothing to disclose.
- Sunali Wahedra, MD, Medical Director of Med Learning Group, has nothing to disclose.
- Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
- Jessica Feygin, Associate Program Manager of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
- Daniel DaSilva, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
Please listen to the podcast below:
RELEASED DATE: January 26, 2024
EXPIRATION DATE: January 26, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
